Lipids and stroke

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 3, 2003, Pages 170-176

  Buckley, Brendan M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cholesterol; HDL; HMG CoA reductase inhibitor; LDL; Lipoprotein fibrate; Risk factors; Statin; Stroke; Triglycerides

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN;

CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG EFFICACY; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; PATHOGENESIS; REVIEW; RISK FACTOR; STROKE; VASCULAR DISEASE;

EID: 0037898544     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030030301     Document Type: Review

References (46)

1. Wannamethee SG, Shaper AG, Ebrahim S. HDL cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000; 311:882-8.
2. Shahar E, Chambless LE, Rosamond WD et al. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2003;34:623-31.
3. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.
4. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Jr., Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomised, controlled trials. Ann Intern Med 1993;119:136-45.
5. Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904-10.
6. Benfante R, Yano K, Hwang LJ, Curb JD, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 1994;25:814-20.
7. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002;33:1863-8.
8. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-80.
9. Whisnant JP. Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke 1997;28:1840-4.
10. Sridharan R. Risk factors for ischemic stroke: a case control analysis. Neuroepidemiology 1992;11:24-30.
11. Sacco RL, Benson RT, Kargman DE et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001;285:2729-35.
12. Bots ML, Elwood PC, Nikitin Y et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002;56(suppl 1):i19-24.
13. Davis B, Vogt T, Frost PH et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke 1998;29:1333-40.
14. Simons LA, McCallum J, Friedlander Y, Simons J. Risk factors for ischemic stroke. Stroke 1998;29:1341-6.
15. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8,586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28:83-7.
16. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001;159:201-08.
17. Wilt TJ, Rubins HB, Robins SJ et al. Carotid atherosclerosis in men with low levels of HDL cholesterol. Stroke 1997;28:1919-25.
18. Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. Stroke 1997;28:518-25.
19. Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001;104:2892-7.
20. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001;159:201-08.
21. Sacco RL. Newer risk factors for stroke. Neurology 2001;57:S31-4.
22. MacLeod MJ, De Lange RP, Breen G, Meiklejohn D, Lemmon H, Clair DS. Lack of association between apolipoprotein E genoype and ischaemic stroke in a Scottish population. Eur J Clin Invest 2001;31:570-3.
23. Slooter AJC, Bots ML, Havekes LM et al. Apolipoprotein E and Carotid Artery Atherosclerosis: The Rotterdam Study. Stroke 2001;32:1947-52
24. Djousse L, Myers RH, Province MA et al. Influence of Apolipoprotein E, Smoking, and Alcohol Intake on Carotid Atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke 2002;33:1357-61.
25. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
26. Bloomfield Rubins H, Davenport J, Babikian V et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33.
27. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomised, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-50.
28. Sacks FM, Moye LA, Davis BR et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97:1446-52.
29. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18.
30. Corvol J, Bouzamondo A, Sirol M, Hulot J, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention. A meta-analysis of randomised trials. Arch Intern Med 2003;163:669-76.
31. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
32. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
33. Sever PS, Dahlöf B, Poulter N et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
34. Byington RP, Jukema JW, Salonen JT et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92: 2419-25.
35. Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002;106:1690-5.
36. Pedersen TR, Kjekshus J, Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-5.
37. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators (see comments). N Engl J Med 1996;335:1001-09.
38. The Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-57.
39. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-07.
40. Byington RP, Davis BR, Plehn JF et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103:387-92.
41. Shipley MJ, Pocock SJ, Marmot HG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18-year follow-up of the Whitehall Study. BMJ 1991;303:89-92.
42. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-23.
43. Shepherd J, Blauw GJ, Murphy MB et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999;84:1192-7.
44. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol (see comments) (published erratum appears in Lancet 1997; 349:214). Lancet 1996;348:1079-82.
45. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999;30:1969-73.
46. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28:2315-20.